ImmuCell (ICCC) Stock Price, News & Analysis

Company Overview

ImmuCell Corporation (NASDAQ: ICCC) is a biotechnology company focused on developing and commercializing products that support the health and productivity of dairy and beef cattle. The company uses antibody-based and other biological technologies to address common livestock diseases and conditions, with an emphasis on products that can be administered conveniently on farms.

ImmuCell’s primary commercial product is the First Defense line, which is designed to help protect newborn calves from bovine neonatal diarrhea, a condition associated with pathogens including rotavirus, coronavirus and Escherichia coli. The company has also developed Re-Tain, an intramammary treatment intended for use against subclinical mastitis caused by Staphylococcus aureus in lactating dairy cattle.

Founded in 1987 and headquartered in Portland, Maine, ImmuCell conducts product development, manufacturing and commercialization activities in the United States. Its products are marketed to the livestock health and dairy industries, with the company’s operations primarily centered on North American cattle producers and related animal-health distribution channels.

Key Stats

• Today's Range: $9.65 to $9.80
• 50-Day Range: $9.58 to $11.07
• 52-Week Range: $4.52 to $12.10
• Volume: 1,860 shs
• Average Volume: 12,543 shs
• Market Capitalization: $88.98 million
• P/E Ratio: 122.52
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Hold

ImmuCell Stock Analysis - MarketRank™

ImmuCell scored higher than 10% of companies evaluated by MarketBeat, and ranked 841st out of 881 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 1.2 / 5
• Analyst Rating: Hold

Consensus Rating

ImmuCell has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no strong buy ratings, no buy ratings, 1 hold rating, and no sell ratings.

Amount of Analyst Coverage

ImmuCell has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of ImmuCell is 122.52, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 39.00.

Price to Earnings Ratio vs. Sector

The P/E ratio of ImmuCell is 122.52, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 274.15.

Price to Book Value per Share Ratio

ImmuCell has a P/B Ratio of 3.28. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.26% of the float of ImmuCell has been sold short.

Short Interest Ratio / Days to Cover

ImmuCell has a short interest ratio ("days to cover") of 1.76, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in ImmuCell has recently increased by 11.52%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

ImmuCell does not currently pay a dividend.

Dividend Growth

ImmuCell does not have a long track record of dividend growth.

News and Social Media

• Score: 0.0 / 5
• News Sentiment: N/A

News Coverage This Week

MarketBeat has tracked 1 news article for ImmuCell this week, compared to 2 articles on an average week.

Company Ownership

• Score: 0.4 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, ImmuCell insiders have not sold or bought any company stock.

Percentage Held by Insiders

5.70% of the stock of ImmuCell is held by insiders.

Percentage Held by Institutions

13.47% of the stock of ImmuCell is held by institutions.

Company Calendar

• Last Earnings: 8/13/2026
• Today: 10/10/2026
• Next Earnings (Estimated): 11/12/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Pharmaceuticals
• Sub-Industry: Pharmaceuticals
• Current Symbol: NASDAQ:ICCC
• CIK: 811641
• Web: www.immucell.com
• Phone: (207) 878-2770
• Fax: 207-878-2117
• Employees: 73
• Year Founded: 1982

Profitability

• EPS (Trailing Twelve Months): $0.08
• Trailing P/E Ratio: 122.52
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$1.04 million
• Net Margins: 2.57%
• Pretax Margin: 2.78%
• Return on Equity: 2.69%
• Return on Assets: 1.76%

Debt

• Debt-to-Equity Ratio: 0.22
• Current Ratio: 4.75
• Quick Ratio: 2.71

Sales & Book Value

• Annual Sales: $27.64 million
• Price / Sales: 3.22
• Cash Flow: $0.19 per share
• Price / Cash Flow: 50.57
• Book Value: $2.99 per share
• Price / Book: 3.28

Miscellaneous

• Outstanding Shares: 9,080,000
• Free Float: 8,564,000
• Market Cap: $88.98 million
• Optionable: Not Optionable
• Beta: 0.56